ALSO NOTED: BioSeek to collaborate with Merck KGaA; BioAlliance acquires drug rights; and much more...

> BioSeek has forged a collaboration deal with Merck KGaA to evaluate the potential of small molecules and proteins. Release

> BioAlliance Pharma has acquired the European rights to ondansetron Oral Spray, which is being developed by NovaDel Pharma. NovaDel gets a $3 million licensing fee and up to $24 million in milestones. Release

> Dr. Dale Bredesen is leaving the Buck Institute for Age Research and launching Prevarex, which will help people understand more about medical research and advances in diagnostics. Report

> A U.S. court hearing over Seroquel's patents has been bumped forward to today from June 4, boosting speculation that the drugmaker might just come out on top in the high-stakes case. AstraZeneca report

> Rep. Bart Stupak might be a severe FDA critic, but he's also shaping up to be the agency's dearest friend. Chief of the House Energy and Commerce committee's oversight-and-investigations group, Stupak helped push FDA commissioner Andrew von Eschenbach to ask for millions more in FDA funding. FDA report

> The British press is abuzz today with the fact that outgoing GlaxoSmithKline CEO Jean-Pierre Garnier abruptly ended a BBC interview when it turned adversarial. Report

And Finally… The Massachusetts Biotechnology Council and the American Cancer Society are raising $1.4 million to fund three years of research by 10 Massachusetts cancer scientists. Story

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.